The knockdown of the NFE2L2 gene in AML cell lines THP1 and U937 sensitized them to the daunorubicin and arsenic trioxide treatment by reducing the reactive oxygen scavenging capacity and downregulation of the target antioxidant genes. This evidence concerns the gene NFE2L2 and acute myeloid leukemia.